Pathophysiology and Pre-Operative Evaluation of Patients at Risk for Intraoperative Floppy Iris Syndrome (IFIS)

Matthew A. Cantrell¹, Heather R. Bream-Rouwenhorst¹, Christopher Watts² and Thomas A. Oetting²
¹University of Iowa College of Pharmacy, Department of Pharmacy Practice and Science, Iowa City, Iowa
²University of Iowa Carver College of Medicine, Iowa City, Iowa USA

1. Introduction

Intraoperative Floppy Iris Syndrome (IFIS) has received a significant amount of attention and subsequent research since it was first reported in 2005 (Bell et al., 2009; Blouin et al., 2007; Chang & Campbell, 2005; Chang et al., 2007; Oshika et al., 2007; Srinivasan et al., 2007; Takmaz & Can, 2007). Current and former uses of alpha-1 adrenergic receptor (α₁AR) antagonists—most notably tamsulosin—appear to be at the highest risk for this surgical complication (Chang & Campbell, 2005). IFIS is characterized by loss of muscle tone in the iris, thereby preventing mydriasis and involves a triad of pupil constriction, fluttering and billowing of the iris stroma, and propensity for iris prolapse during cataract surgery (Chang & Campbell, 2005). While α₁AR antagonists are often used for various urological conditions, they also block α₁AR receptors in the iris dilator muscle and may worsen muscle tone and lead to the iris billowing sometimes seen in cataract surgery. Without adequate pupil dilation, IFIS reduces visualization of the surgical field, including the cataract itself. This impairs removal and can lead to other complications including rupture of the posterior capsule, which further increases the risk of other vision-threatening complications of cataract surgery (Schwinn & Afshari, 2006).

2. Use of alpha-1 adrenergic receptor (AR) antagonists

Since there is a significant association between α₁AR antagonist use and IFIS, a brief review of the indications of α₁AR antagonists is necessary to identify the at-risk population. The principal indication is treatment of benign prostatic hyperplasia (BPH). This urological disorder shares risk factors with cataract development, with advanced age being the most significant (Congdon et al., 2004). If left untreated, BPH increases risk for significant complications including acute urinary retention, recurrent urinary tract infections, and urinary incontinence (Crawford et al., 2006). In patients with mild BPH as indicated by an American Urological Association (AUA) scores of 8 or less, pharmacotherapy may not be indicated as lower urinary tract symptoms (LUTS) often improve spontaneously. Identifying
suitable candidates for this strategy, often called “watchful waiting,” is critical to reduce unnecessary exposure to $\alpha_1$AR therapy and is recommended by the AUA to invariably reduce risk for IFIS (American Urological Association [AUA], 2010). Pharmacotherapy for BPH is indicated in patients with moderate to severe disease and includes the 5-alpha reductase inhibitors (5ARI) and $\alpha_1$AR receptor antagonists. The 5ARI finasteride and dutasteride inhibit conversion of testosterone to dihydrotestosterone, thereby shrinking the prostate; the $\alpha_1$AR antagonists reduce bladder outlet obstruction by relaxing prostatic smooth muscle tissue surrounding the urethra. The currently available agents include terazosin, doxazosin, alfuzosin, tamsulosin, and silodosin. They have comparable effects in symptom reduction (Djavan et al., 2004; Marks et al., 2009). While terazosin and doxazosin were originally developed for treatment of hypertension, their use for this indication has waned largely due to publication of the ALLHAT trial which demonstrated a higher incidence of hospitalization for congestive heart failure (CHF) in the doxazosin arm relative to chorthalidone (ALLHAT, 2000). Subsequent “uroselective” agents that target the $\alpha_{1A}$ AR have been developed including tamsulosin, and most recently silodosin. (Package insert Flomax 2007; Package insert Rapaflo 2008). Alfuzosin’s improved tolerability is largely attributable to its extended-release formulation, which prevents peaks in serum concentrations (Roehrborn et al., 2000)

Aside from the robust data demonstrating benefit in men with BPH, these agents have an emerging role in other areas of urology including facilitating the passage of urinary calculi, as an adjunctive treatment for chronic prostatitis, following ureteral stent placement, and also improving symptoms of overactive bladder in select patients (Anothaisintawee et al., 2011; Kaplan et al., 2006; Navanimitkul & Lojanapiwat, 2010; Singh et al., 2007). Use of $\alpha_1$AR is limited outside the urological arena; however, some patients are undoubtedly still taking them for treatment refractory hypertension. Finally, data suggests that prazosin—an agent no longer endorsed by the AUA for treatment of BPH due to its unfavorable adverse effect and pharmacokinetic profile—has been shown to be effective in reducing nightmares secondary to post-traumatic stress disorder (PTSD) (Dierks et al., 2007; Raskind et al., 2003).

It is imperative that ophthalmologists recognize the various indications for $\alpha_1$AR therapy to identify those at risk for IFIS. While men are at higher risk based on their respective use of $\alpha_1$AR for treatment of BPH, physicians should recognize that some women may be taking these agents for other indications as well.

3. Pathophysiology of IFIS

The $\alpha_1$ARs are G-protein coupled receptors and subdivided into $\alpha_{1A}$AR, $\alpha_{1B}$AR, and $\alpha_{1D}$AR subtypes. Stimulation of $\alpha_1$AR elicits contraction of cardiac and most innervated vascular smooth muscle throughout the body (Biaggioni & Robertson, 2009). Like the iris dilator muscle, the prostate contains a significant volume of smooth muscle rich in ARs. BPH and its associated LUTS involve the prostate, urethra, bladder, and spinal cord. The $\alpha_{1A}$ and $\alpha_{1D}$AR predominate in these organs, but $\alpha_{1B}$AR are also present. As the prostate grows in BPH, there is upregulation of $\alpha_1$AR expression, with studies demonstrating that expression of $\alpha_{1A}$ARs increases up to 9-fold and $\alpha_{1D}$ARs by 3-fold. This upregulation, especially of $\alpha_{1A}$AR, is thought to be responsible for the disproportionate increase in smooth muscle contraction and worsening of LUTS in patients with BPH (Thiyagarajan, 2002). Therefore, $\alpha_1$AR antagonists are useful in ameliorating symptoms associated with BPH by decreasing prostatic urethral resistance although this blockade may influence iris behavior (Shapiro et
al., 1992). Specifically, use of $α_1$AR antagonists for BPH relieves straining and hesitancy, improves bladder emptying, and increases the force of the urinary stream. Commonly used second-generation $α_1$AR antagonists include doxazosin and terazosin, although patient tolerability to these agents is variable, with the most vexing clinical problems being orthostatic hypotension and dizziness (McNaughton-Collins & Barry, 2005). Frail geriatric patients often suffer from gait problems, and the addition of a medication that could increase the potential of a fall is undesirable. The increased $α_{1A}AR$ selectivity of the third-generation “uroselective” agents tamsulosin and silodosin is postulated to provide additional relief of LUTS in patients with BPH without increasing the rate of serious adverse cardiovascular effects due to systemic $α$AR antagonism. (Cantrell et al., 2008; Cantrell et al., 2010)

$α_1$AR antagonists not only therapeutically inhibit prostatic $α_1$AR but may also selectively antagonize these receptors in the iris dilator muscle. In the iris, $α_{1A}AR$ mediate iris dilator smooth muscle contraction whereas iris arteriolar contraction is mediated via $α_{1B}AR$. Blockade of this muscle’s $α$AR is hypothesized to lead to poor muscle tone and the subsequent iris billowing sometimes seen in cataract surgery (Schwinn & Afshari, 2006). Figure 1 illustrates the clinical dilemma of IFIS and the subsequent potential for surgical complications.

![Iris damage following cataract surgery in a patient taking tamsulosin](image)

Adapted or Reprinted with permission from 'Editorials: Floppy Iris Syndrome: Why BPH Treatment Can Complicate Cataract Surgery,' June 15, 2009, American Family Physician. Copyright © 2009 American Academy of Family Physicians. All Rights Reserved

Fig. 1. Iris damage following cataract surgery in a patient taking tamsulosin

Although Chang and Campbell first associated IFIS with tamsulosin in 2005, other available $α_1$AR antagonists were subsequently linked to IFIS as well (Dhingra et al., 2007; Herd, 2007; Package insert Rapaflo, 2008; Settas & Fitt, 2006; Venkatesh et al., 2007).
Potentially, the high $\alpha_{1A}$AR-specific antagonism of tamsulosin made the association easier to identify. In rabbits, tamsulosin was more effective than the non-specific $\alpha$AR antagonist alfuzosin at blocking adrenergic-mediated iris dilator contraction (Palea et al., 2008). Interestingly, functional studies assessing the affinity of different ARs as measured by pKi (negative logarithm of the equilibrium dissociation constant) reflect higher affinity of silodosin for $\alpha_{1A}$AR compared to older agents; when compared to other currently available $\alpha_1$AR antagonists, silodosin is 1400 times more specific in terms of $\alpha_{1A}$AR versus $\alpha_{1B}$AR binding than doxazosin and terazosin and 40 times greater compared to tamsulosin (Thiyagarajan, 2002). It remains to be seen if silodosin has a greater likelihood to cause IFIS than the other available agents.

In a rabbit study, Palea et al. suggested an additional unrecognized receptor may be involved in contraction of the iris dilator muscle as $\alpha_1$AR blockade with tamsulosin and alfuzosin was less prominent in the iris than the prostate (Palea et al., 2008). While $\alpha_{1A}$AR are commonly reported as the predominant subtype in the iris dilator muscle in animal studies (Suzuki et al., 2002; Yu & Koss, 2003), Flach pointed out that assuming $\alpha_{1A}$AR predominate in the human iris dilator muscle based off rabbit studies may be misleading (Flach, 2009). Nevertheless, human immunohistochemical analysis has shown $\alpha_{1A}$ARs to localize to iris arteriolar muscularis and the iris dilator muscle (Panagis et al., 2010).

4. Risk factors for IFIS

The most comprehensive assessment of risk factors for IFIS was recently published. This meta-analysis included seventeen studies totaling 17,588 eyes (Chatziralli & Sergentanis, 2010). It assessed current use of $\alpha_1$AR antagonist therapy as well as the effect of co-variates hypertension and diabetes. Current tamsulosin use was associated with the highest risk among the groups studied. Current use of alfuzosin and terazosin was associated with lower risk relative to tamsulosin but remained statistically significant. The pooled analysis of doxazosin did not reach statistical significance; however, the authors cautioned that more studies are needed to gain statistical power. Of the covariates tested, only current hypertension increased risk for IFIS. Despite mixed results in various studies, diabetes did not emerge as a significant risk factor for IFIS. The authors concluded that, consistent with previous reports, it appears that tamsulosin use is associated with the highest risk of IFIS relative to other agents.

There is limited information regarding doxazosin, prazosin and the most recently approved agent silodosin. However, as the latter’s pharmacology most resembles tamsulosin and because of its high affinity for the $\alpha_{1A}$AR, it should be presumed that there is an inherent risk with silodosin until data suggests otherwise. A complete list of medications associated with IFIS is described in Table 1.

5. Literature review

IFIS was originally reported in a retrospective study of 511 patients who underwent cataract surgery (Chang & Campbell, 2005). Twenty-seven patients (5.3%) totaling 40 eyes had preoperative exposure to $\alpha_1$AR antagonists. Ten of sixteen (62.5%) patients who received tamsulosin prior to surgery developed IFIS. In the remaining eleven patients on other $\alpha_1$AR antagonists, there were no documented cases of IFIS. However, the authors
reported that all twenty-seven patients had “poor or moderately poor dilation.” A complete list of studies assessing incidence of IFIS as well as studies assessing rates of surgical complications in patients prescribed $\alpha_1$AR antagonists are described in Table 2.

**Alpha-1 adrenergic receptor (AR) antagonists**

<table>
<thead>
<tr>
<th>Medication</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>tamsulosin</td>
<td></td>
</tr>
<tr>
<td>terazosin</td>
<td></td>
</tr>
<tr>
<td>doxazosin</td>
<td></td>
</tr>
<tr>
<td>alfuzosin</td>
<td></td>
</tr>
<tr>
<td>prazosin</td>
<td></td>
</tr>
<tr>
<td>silodosin</td>
<td></td>
</tr>
</tbody>
</table>

**Miscellaneous medications**

<table>
<thead>
<tr>
<th>Medication</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>finasteride</td>
<td></td>
</tr>
<tr>
<td>saw palmetto</td>
<td></td>
</tr>
<tr>
<td>donepezil</td>
<td></td>
</tr>
<tr>
<td>risperidone</td>
<td></td>
</tr>
<tr>
<td>chlorpromazine</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Medications associated with IFIS

In a prospective analysis of 900 consecutive cataract surgeries among 741 patients, IFIS was observed in sixteen patients (2.2%), fourteen of whom had documented concomitant use of tamsulosin (Chang & Campbell, 2005). In the two remaining patients, one had discontinued tamsulosin three years prior to surgery, and one had no history of tamsulosin exposure. Furthermore, IFIS was reported in both eyes of the five patients taking tamsulosin that required bilateral cataract surgery.

Despite the authors’ initial identification of a potentially serious complication of cataract surgery, reported limitations of the study include lack of covariate data and the modest reported use of $\alpha_1$AR antagonists at 1.9% (Chang & Campbell, 2005; Schwinn & Afshari, 2006). As stated above, patients with BPH may not always require pharmacologic treatment, specifically in patients with mild American Urological Association (AUA) symptom scores (AUA, 2010). This may partially explain the relatively low percentage of tamsulosin use in a population with a historically high prevalence of BPH.

In a recent study assessing incidence, IFIS was reported to be 1.6% among 774 patients (Takmaz & Can, 2007). IFIS was documented in 14 of 18 patients (77.8%) taking tamsulosin, and consistent with the original report by Chang and Campbell, tamsulosin use overall was observed in 2.2% of patients. Duration of tamsulosin use—although increased among patients diagnosed with IFIS—was not statistically significant relative to those without IFIS.

A recent study directly compared the incidence of IFIS attributable to tamsulosin with an active comparator group. (Blouin et al., 2007). In this retrospective study of 64 men totaling 92 eyes, there was an increased risk of IFIS in patients exposed to tamsulosin (86.4%) when compared to alfuzosin (15.4%). The adjusted odds ratio for IFIS in patients taking tamsulosin when compared to alfuzosin was 32.15 (95% confidence interval, 2.74-377.41). Furthermore, a five-fold increase in surgical complication rates was observed in patients diagnosed with IFIS, highlighting its clinical significance.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Design</th>
<th>Objective</th>
<th>Population</th>
<th>Overall Prevalence or Incidence of IFIS (%)</th>
<th>Exposure to Systemic α₁AR Antagonist (%)</th>
<th>Prevalence or Incidence of IFIS in Tamsulosin-Treated Patients (%)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chang &amp; Campbell, 2005</td>
<td>Clinical study 1: retrospective chart review</td>
<td>Assess incidence and possible causative factors of IFIS</td>
<td>511 patients; 706 eyes</td>
<td>10/511 patients (2.0)</td>
<td>27/511 patients (5.3)</td>
<td>10/16 patients (62.5)</td>
<td>Chang &amp; Campbell, 2005 Clinical study 1: retrospective chart review Assess incidence and possible causative factors of IFIS 511 patients; 706 eyes 10/511 patients (2.0) 27/511 patients (5.3) 10/16 patients (62.5)</td>
</tr>
<tr>
<td>Chang &amp; Campbell, 2005</td>
<td>Clinical study 2: prospective case series</td>
<td>Evaluate surgical outcomes and rate of complications when ophthalmologist knew patient was taking tamsulosin</td>
<td>441 patients; 900 eyes</td>
<td>16/441 patients (3.6)</td>
<td>Not available</td>
<td>15/16 patients (93.8)</td>
<td>Chang &amp; Campbell, 2005 Clinical study 2: prospective case series Evaluate surgical outcomes and rate of complications when ophthalmologist knew patient was taking tamsulosin 441 patients; 900 eyes 16/441 patients (3.6) Not available 15/16 patients (93.8)</td>
</tr>
<tr>
<td>Chang et al., 2007</td>
<td>Retrospective chart review</td>
<td>Compare IFIS risk in men taking tamsulosin vs. alfuzosin</td>
<td>332 patients; 461 eyes</td>
<td>61/461 patients (13.2)</td>
<td>64/332 patients (19.3)</td>
<td>19/22 patients (86.4)</td>
<td>IFIS in 2/13 (15.4%) patients exposed to alfuzosin</td>
</tr>
<tr>
<td>Srinivasan et al., 2007</td>
<td>Retrospective chart review</td>
<td>Determine occurrence of IFIS in those exposed to systemic α₁AR antagonists</td>
<td>1298 patients; 1612 eyes</td>
<td>13/1298 patients (1.0)</td>
<td>65/1298 patients (5.0)</td>
<td>10/13 patients (76.9)</td>
<td>IFIS in 2 patients exposed to terazosin and 1 patient exposed to doxazosin</td>
</tr>
<tr>
<td>Takmaz &amp; Can, 2007</td>
<td>Prospective, nonrandomized observational study</td>
<td>Evaluate complication rates, effect of intracameral adrenaline, and incidence of IFIS in patients taking tamsulosin</td>
<td>774 patients; 858 eyes</td>
<td>16/858 patients (1.9)</td>
<td>24/858 patients (2.8)</td>
<td>14/18 eyes (77.8)</td>
<td>IFIS in 1 of 4 eyes exposed to terazosin and 1 of 2 eyes exposed to alfuzosin</td>
</tr>
<tr>
<td>Oshika et al., 2007</td>
<td>Prospective, interventional case series</td>
<td>Compare incidence of IFIS with topical vs. systemic α₁AR antagonists</td>
<td>1968 patients; 2643 eyes</td>
<td>29/2643 patients (1.1)</td>
<td>134/2643 patients (5.1)</td>
<td>25/58 patients (43.1)</td>
<td>No IFIS in bunazosin (topical α₁AR antagonist which is not α₁AAR-specific) group</td>
</tr>
</tbody>
</table>
Pathophysiology and Pre-operative Evaluation of Patients at Risk for Intraoperative Floppy Iris Syndrome (IFIS)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Design</th>
<th>Objective</th>
<th>Population</th>
<th>Overall Prevalence or Incidence of IFIS (%)</th>
<th>Exposure to Systemic α1AR Antagonist (%)</th>
<th>Prevalence or Incidence of IFIS in Tamsulosin-Treated Patients (%)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amin et al. (2008)</td>
<td>Prospective observational study</td>
<td>Assess incidence of IFIS associated with tamsulosin</td>
<td>1267 patients; 1462 eyes</td>
<td>Not available</td>
<td>Not available</td>
<td>13/23 eyes (56.5)</td>
<td></td>
</tr>
<tr>
<td>Keklikci et al. (2009)</td>
<td>Prospective, nonrandomized observational study</td>
<td>Assess incidence of IFIS associated with tamsulosin</td>
<td>579 patients; 594 eyes</td>
<td>15/579 eyes (2.6)</td>
<td>Not available</td>
<td>12/23 patients (52.2)</td>
<td></td>
</tr>
<tr>
<td>Chen et al. (2010)</td>
<td>Retrospective cohort study</td>
<td>Determine incidence of IFIS in patients taking tamsulosin, effect of prophylactic measures</td>
<td>1163 eyes</td>
<td>Not available</td>
<td>Not available</td>
<td>24/81 eyes (29.6)</td>
<td></td>
</tr>
<tr>
<td>Horvath &amp; Vultur (2011)</td>
<td>Prospective, nonrandomized observational study</td>
<td>Report incidence, etiology and management of IFIS</td>
<td>438 patients; 439 eyes</td>
<td>37/439 eyes (8.4)a</td>
<td>15/439 eyes (3.4)</td>
<td>Incidence of IFIS in patients treated w/α1AR = 86.7%</td>
<td></td>
</tr>
</tbody>
</table>

*a* Includes patients that experienced an IFI-like syndrome

Table 2. Incidence and prevalence of IFIS in selected studies

Following the original report suggesting a stronger link between tamsulosin and IFIS relative to other α1AR antagonists, subsequent case reports of IFIS have been published in men taking alfuzosin, doxazosin, and terazosin (Dhingra et al., 2007; Herd, 2007; Settas & Fitt, 2006; Venkatesh et al., 2007).

Aside from IFIS, α1AR antagonist therapy prior to cataract surgery has been shown to predispose patients to complications following cataract surgery (Bell et al., 2009). A nested case control study examined health care records of 96,128 Canadian men aged 66 years or older who had undergone cataract surgery over a 5 year period. Post-operative complications that were examined included retinal detachment, lost lens or lens fragment, or endophthalmitis. Overall, 3.7% had a history of exposure to tamsulosin, and 7.7% had recently taken other alpha blockers. Cases—that is men with a history of complications—were matched to control patients. The authors identified complications in 280 patients (0.3%). These cases were randomly matched to control patients based on age, surgeon, and year of procedure. Complications were more common among current users of tamsulosin. This risk was not significantly increased with exposure to other α1AR antagonists or to previous exposure to tamsulosin or other α1AR antagonists. However, tamsulosin use within 14 days of cataract surgery increased the risk for complications.
Currently, risk of IFIS has only been associated with systemic use of α1AR antagonists. In a study comparing the incidence of IFIS between topical and systemic administration, no cases were observed in patients taking bunazosin, a topical, non-selective, α1AR antagonist which is not currently available in the United States (Oshika et al., 2007). In the tamsulosin comparator group, the incidence of IFIS was 1.1%. Notably, results may have differed had the topical agent used also been specific for the α1AAR subtype.

In response to multiple reports of an increased risk of IFIS, the package labeling of tamsulosin and other α1AR antagonists has been updated to reflect this potential risk. The labeling further acknowledges that benefits of stopping an α1AR antagonist prior to cataract surgery remains unknown (Package insert Flomax, 2007).

The 5ARI finasteride and the extract of saw palmetto (Serona repens) a type of palm plant utilized largely as alternative medicine for treatment of BPH have been linked to IFIS (Issa & Dagres, 2007; Yeu & Grostern, 2007). The patients in the aforementioned cases were specifically stated to not have received α1AR antagonists prior to cataract surgery; however, the possibility exists that the patients may have received an unrecognized α1AR antagonist either currently or in the past. No mechanism for how these agents may cause IFIS has been postulated, and the effect of how 5ARIs interact with the iris has not been studied. While confounders common to patients taking either 5ARIs or α1AR antagonists such as increased age or male gender cannot be ruled out, certainly the strongest evidence of a link between medication and IFIS is with α1AR antagonists and not 5ARIs.

Aside from α1AR antagonists, IFIS has been associated with other medications as well. Lending credence to the theory that α1AR antagonism is heavily responsible for IFIS, the antipsychotics chlorpromazine and risperidone, both mild α1AR antagonists, have been linked to IFIS in patients not previously haven received conventional α1-AR antagonists (Ford et al., 2011; Unal et al., 2007). Labetalol, a dual α1- and β-AR antagonist, has also been associated with IFIS (Calotti & Steen, 2007).

One case of acetylcholinesterase-inhibitor-associated IFIS with donepezil has been reported. The authors hypothesized that through enhancement of cholinergic activity on the pupil sphincter, the pharmacological effect of the preoperative dilating drops was overcome (Papadopoulos & Bachariou, 2007). The patient reportedly had never received an α1AR antagonist. However, a complete medication list was not documented in the case, and receipt of other α1AR antagonists cannot be ruled out.

6. Pre-operative evaluation

The relationship of α1AR antagonists to IFIS has changed the preoperative process for cataract surgeons. The pre-operative evaluation is particularly difficult as there is currently no reliable way to predict which patients will demonstrate IFIS. Furthermore as IFIS can present unilaterally the absence in one eye does not preclude the other eye from demonstrating features of IFIS in a subsequent surgery (Issa et al., 2008). During the pre operative visit, there are a number of questions and observations which may highlight for the surgeon any patients at potential risk for IFIS.

Most importantly is to ask all patients about current or former use of α1AR antagonists. Simply reviewing the current medication list is not sufficient. Many patients are unable to recall specific medication names or classes they are currently taking, much less a medication they took previously and since discontinued. Because of this, often times asking a patient or an accompanying family member if they have ever been treated for an enlarged prostate or
for difficulty emptying their bladder will help elicit a more accurate history. If a patient does have a history of $\alpha_1$AR antagonists it is also important to counsel them on the associated increased risk of IFIS and subsequent risk of complications postoperatively.

The most reliable preoperative predictive feature of IFIS in a patient with a history of $\alpha_1$AR antagonists is poor pupillary dilation (Oetting, 2009). This can and should be noted during the office pre-operative cataract surgery evaluation, and not just on the day of surgery. When the pupil does not dilate well, the surgeon should be wary of IFIS during surgery. Although poor dilation can also be a harbinger of other intraocular conditions such as pseudoexfoliation and trauma, recognition will help the surgeon prepare for and adapt intraoperative management strategies for all possible complications (Altan-Yaycioglu et al., 2007).

7. Conclusion

Recognizing patients at risk for IFIS is paramount to management. Without adequate preparation and management IFIS and subsequent postoperative complications are possible. A detailed pre-operative evaluation including recognizing those at risk for IFIS will ensure the best outcome.

8. References


Roehrborn, CG.; for the ALFUS STUDY GROUP. (2001). Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign


